Therefore, across most European countries, evaluation of patients for adjuvant anti-PD-1-based immunotherapy after complete melanoma resection is a cornerstone of the shared decision-making strategy for patients with stage ≥IIB melanoma, i.e. for all patients with stage IIB/C and IIIA melanoma, and patients with non-macroscopic stage ≥IIIB melanoma. Here, PDCD1 is linked to melanoma.